Weekly Digest – June 2024 Weekly Digest – June 2024 27 June 2024: Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer TUB-040 is a next-gen NaPi2b-targeting Exatecan ADC using proprietary P5 technology, now […]
Weekly Digest – June 2024 Weekly Digest – June 2024 26 June 2024: Daiichi’s lung cancer ADC rejected by FDA in blow to first project under Merck partnership The FDA rejected Daiichi Sankyo’s and Merck & Co.’s ADC patritumab deruxtecan […]
Weekly Digest – June 2024 Weekly Digest – June 2024 24 June 2024: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer The U.S. FDA granted Fast Track designation for BNT324/DB-1311 for treating […]
